SCHEMBL9945409

SCHEMBL9945409

CC(C)Oc1cc(C(=O)NC2CN(CC3CC3)C2)ccc1Nc1ncc2c(n1)N(C1CCCC1)CC(C)(C)C(=O)N2C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 15/20 0.62
BRD4 O60885 7/20 0.62
BRDT Q58F21 5/20 0.62
TAF1 P21675 2/20 0.57
ALK Q9UM73 1/20 0.55
RAD52 P43351 1/20 0.54
PLK3 Q9H4B4 4/20 0.52
PLK2 Q9NYY3 2/20 0.52
PTK2 Q05397 2/20 0.52
PDXK O00764 1/20 0.52
WEE1 P30291 1/20 0.52
NEK3 P51956 1/20 0.52
CAMKK2 Q96RR4 1/20 0.52
PRKD3 O94806 1/20 0.52
MAP4K4 O95819 1/20 0.52
PRKCG P05129 1/20 0.52
CLK2 P49760 1/20 0.52
RPS6KA3 P51812 1/20 0.52
NEK4 P51957 1/20 0.52
CAMK2G Q13555 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2397662 0.94 PLK1 (0.70) PLK1BRD4BRDTALKRAD52
SCHEMBL9945408 0.91 PLK1 (0.63) PLK1BRD4BRDTTAF1ALK
SCHEMBL2396519 0.90 PLK1 (0.71) PLK1BRD4BRDTTAF1ALK
SCHEMBL2396512 0.90 PLK1 (0.71) PLK1BRD4BRDTTAF1ALK
SCHEMBL2399437 0.89 PLK1 (0.76) PLK1BRD4BRDTTAF1ALK
SCHEMBL2398538 0.88 PLK1 (0.75) PLK1BRD4BRDTTAF1ALK
SCHEMBL2397009 0.87 PLK1 (0.60) PLK1BRD4BRDTTAF1ALK
SCHEMBL2396772 0.86 PLK1 (0.69) PLK1BRD4BRDTRAD52PLK3
SCHEMBL2398513 0.86 PLK1 (0.75) PLK1BRD4BRDTALKRAD52
SCHEMBL2399311 0.86 PLK1 (0.79) PLK1BRD4BRDTRAD52PLK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120271045-A1 METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-10-25 US disclosed
US-20120271045-A1 METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-10-25 US disclosed
US-20120149898-A1 DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-06-14 US disclosed
US-20120149898-A1 DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120271045-A1 METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS DCK, MAP3K5, MAP3K1 PLK1 42/4885BRD4 1592/4885BRDT 1490/4885
US-20120149898-A1 DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K5, MAP4K2 PLK1 89/4885BRD4 536/4885BRDT 833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.